These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9484410)

  • 1. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    Neurology; 1998 Feb; 50(2):573-4. PubMed ID: 9484410
    [No Abstract]   [Full Text] [Related]  

  • 2. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
    Djamshidian A; Poewe W
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET studies and physiopathology of motor fluctuations in Parkinson's disease.
    Linazasoro G; Leenders KL
    Brain; 2004 Aug; 127(Pt 8):E15; author reply E16. PubMed ID: 15277309
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa and the progression of Parkinson's disease.
    Walton-Hadlock JL
    N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
    [No Abstract]   [Full Text] [Related]  

  • 6. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 7. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 8. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST; Woodward WR; Nutt JG
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations.
    Esteban Muñoz J; Martí MJ; Marín C; Tolosa E
    Clin Neuropharmacol; 1997 Jun; 20(3):245-52. PubMed ID: 9197948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Parkinson disease in patients with surgical problems].
    Sobolewski P
    Neurol Neurochir Pol; 2003; 37 Suppl 5():183-8. PubMed ID: 15098345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A; Le Brun Y; Boal D; Zolfaghari M
    Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
    [No Abstract]   [Full Text] [Related]  

  • 13. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.
    Kolls BJ; Stacy M
    Clin Neuropharmacol; 2006; 29(5):292-301. PubMed ID: 16960475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The modern management of Parkinson's disease.
    Quinn N
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):93-5. PubMed ID: 2107279
    [No Abstract]   [Full Text] [Related]  

  • 17. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of Parkinson's disease.
    Münchau A; Bhatia KP
    Postgrad Med J; 2000 Oct; 76(900):602-10. PubMed ID: 11009573
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
    Merello M; Pikielny R; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1997 Apr; 20(2):165-7. PubMed ID: 9099469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.